Simdax levosimendan: Phase IIb ongoing

Oxygen Biotherapeutics provided Imperial College London with a $500,000 grant to expand the ongoing, double-blind, placebo-controlled, U.K. Phase IIb LeoPARDS trial of Simdax to include additional clinical sites. The trial is enrolling about 516 adults who have septic shock to receive 0.05-0.2 ug/kg/min Simdax for 24 hours in combination with standard of care (SOC). Simdax is approved in at least 53 countries to treat acutely decompensated heart failure. ...